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To the Editor: 
We read with interest the article 
of Stephen A. Deppen et al.1 about 
the development and validation of the 
Thoracic Research Evaluation And 
Treatment lung cancer prediction 
model. One of the variables used in the 
model was the 18F-fluorodeoxyglucose 
(FDG) positron emission tomography 
avidity determined by the maximum 
standard uptake value (SUV). Nodules 
with a SUV less than 2.5 were coded 
as not neoplastic, whereas nodules 
with a SUV greater than or equal to 2.5 
were considered cancerous.1 Although 
18-FDG PET is included in recent 
guidelines for diagnosis of lung cancer, 
non cut-off level is suggested.2
The SUV has become an accepted 
parameter in the clinical evaluation of 
suspected malignant pulmonary nod-
ules. According to Vansteenkiste, SUV 
threshold greater than 2.5 should be 
abandoned, because many lesions with 
a SUV less than 2.5 are malignant.3 
There are, in fact, also non-FDG avid 
malignant lung nodules (e.g., adenocar-
cinoma with lepidic aspects, well-dif-
ferentiated adenocarcinoma, carcinoid 
tumors) in which the SUV cut-off of 2.5 
is not reliable. As SUV value increases, 
the risk of lung cancer increases; nev-
ertheless, according to Bryant, a SUV 
from 0 to 2.5 was associated to a 24% 
chance of a nodule to be malignant.4 
As a matter of fact, there are authors 
who suggest a malignancy SUV cut-off 
greater than or equal to 1.0.5
Considering the cut-off level as 
positive or negative could further enhance 
the capability to detect malignancies.
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poor clinical and modeling practice. We 
did not rely on SUV for nodule avidity as 
two-thirds of patients in the development 
cohort did not report a SUV but rather 
the reader’s impression of the nodule.1 
The institutions used in our study rarely 
report SUV for various reasons.2–4 We 
conducted sensitivity analysis by group-
ing the four categories of avidity into 
different combinations, and we reported 
the best prediction model that cross-val-
idated in our data. These analyses were 
not included in the original article due to 
space limitations. From a purely statis-
tical stand point, considering SUV as a 
possibly nonlinear continuous risk vari-
able and not using any cutpoint would be 
the best approach. However, these data 
were not available to us and using a con-
tinuous predictor of risk does not guar-
antee model performance improvement.
Dr. Bertolaccini and colleagues 
suggest using a lower SUV cutoff (<1) 
to increase the sensitivity of the test. If 
applied to our study, then the tradeoff 
would be increased false-positive results 
and decreased specificity of fludeoxy-
glucose F 18 (FDG)-positron emission 
tomography (PET). Our research into 
FDG-PET scans for diagnosis of lung 
nodules found that the imaging modality 
is not as specific as previously thought 
in regions with endemic fungal lung dis-
ease, such as histoplasmosis, that gener-
ate granulomas.5 This result has caused us 
to question the use of FDG-PET for the 
diagnosis of lung cancer in regions where 
endemic infectious lung disease is high.7 
Although we question the usefulness of 
FDG-PET in some instances, it remains a 
highly sensitive test, and in regions of the 
world where infectious lung disease is 
not endemic, like Europe, we have found 
it to be more accurate.6 Because the 
odds ratio for FDG-PET avidity may be 
higher in populations without infectious 
lung disease exposure, we are pursuing 
additional validation datasets to test this 
hypothesis in our TREAT model.
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In Response:
We want to thank Dr. Bertolaccini 
and his colleagues for their interest in 
our Thoracic Research Evaluation and 
Treatment lung cancer prediction model. 
First, we agree with Dr. Bertolaccini 
that relying solely on a single standard 
uptake value (SUV) cutpoint is both 
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Difference in Outcome 
between Types of KRAS 
Mutation May Point 
toward Difference in 
Tumor Biology
To the Editor: 
With interest we read the article 
by Nadal et al.1 entitled “KRAS-G12C 
mutation is associated with poor 
outcome in surgically resected lung 
adenocarcinoma”.
The authors retrospectively studied 
a group of 179 patients with surgically 
resected adenocarcinoma of the lung with 
known KRAS mutational status. The aim 
of this study was to investigate the effects, 
if any, of KRAS mutant subtypes on sur-
vival probabilities. Here, patients with any 
KRAS mutation had significant poorer sur-
vival compared with patients with KRAS 
wild type. In particular, patients with a 
G12C mutation had worse outcome com-
pared with other types of mutation.
We would like to comment on 
this article. First, the authors report that 
patients with a G12C KRAS mutation 
have a poorer prognosis compared with 
other types of KRAS mutations, which is 
illustrated in Figure 1. The authors also 
refer to a univariate analysis presented in 
Table 3 (p.1518). However, the univariate 
analysis provides a comparison between 
G12C KRAS mutation and wild type, but 
not G12C and non-G12C KRAS muta-
tions. A difference in prognosis between 
types of KRAS mutation could possibly 
point toward differences in tumor biol-
ogy. This is relevant data and we would 
like to invite the author to present the 
data of a multivariate analysis compar-
ing G12C and other types of KRAS 
mutations. Furthermore, it is interest-
ing to know how many patients had an 
EGFR mutation among the patients with 
KRAS wild type. This group of patient 
is known to a have favorable prognosis2 
and can provide a relevant bias.
We agree that the prognostic value 
of KRAS mutation is a controversial topic. 
As discussed in the article, two large stud-
ies on KRAS mutational status in resected 
non–small-cell lung carcinoma did not 
found a prognostic value for KRAS muta-
tion or types of mutation.3,4 Over the past 
decade, almost a dozen studies investi-
gated the same question in non–small-
cell lung carcinoma with conflicting 
results. The study by Nadal et al. should 
therefore be interpreted carefully, despite 
methodological differences. Nonetheless, 
the data on KRAS addiction is interesting 
and we hope that future studies will point 
out the clinical relevance.
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made by Dr. Egber Smit and collabora-
tors to our article on KRAS codon vari-
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